Company: SHPH
Filing Date: 2025-11-21
Form Type: 8-K
Source: 0001493152-25-024618
Chunk: 1

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-11-21
Form: 8-K
Item: Item 2.05
Chunk 1
---
Item
2.05. Costs Associated with Exit or Disposal Activities.

The
information set forth above under Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.

On
November 20, 2025, in light of the foregoing, the Company committed to a plan to discontinue its clinical trials of Ropidoxuridine (the
“ Clinical Trials”), as provided for under the Master Agreement. The Company expects to immediately end enrollment and initiate
winddown activities for the Clinical Trials, with full completion of winddown activities expected to occur as soon as practicable in
a manner compliant with the requirements of the Food and Drug Administration.

As
a result of the termination of the Clinical Trials, the Company expects to incur additional expenses related to trial closeout activities.
The Company is currently assessing and estimating these costs and expects that the vast majority of these charges will be recorded in
the fourth quarter of 2025.

The
costs that the Company expects to incur in connection with the foregoing are subject to a number of assumptions, and actual results may
materially differ. The Company may also incur other costs or charges not currently contemplated as a result of, or associated with, the
foregoing events.

Item
2.05 contains “forward-looking” statements and estimates, including anticipated winddown costs. These statements are subject
to a number of risks and uncertainties that could cause actual results to differ materially, including whether the Company will successfully
winddown the Clinical Trials and other risks detailed in the “ Risk Factors” section of the Company’s most recent periodic
report filed with the SEC. These statements represent the Company’s estimates and assumptions only as of the date of this Current
Report on Form 8-K. The Company does not undertake any obligation to update publicly any such forward-looking statements, even if new
information becomes available.